Skip to main content
The Globe and Mail
Support Quality Journalism
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); }

Our roundup of Canadian small-caps of between $100-million and $2.5-billion in market capitalization making news and on the move today.

Liberty Health Sciences Inc. (LHS-CN) reported sales of $16.1-million for the third quarter ended Nov. 30 compared with $3.2-million for the third quarter a year ago. The company recorded net income for the quarter of $6.9-million compared with a net loss of $9.7-million for the same quarter a year earlier.

"The significant year-over-year increase in revenue was driven by the company's opening of new dispensaries and delivery locations, as well as experiencing an increase in same-store sales volume, and an uptick in the registered patient base for medical marijuana use in Florida," it stated in a release.

Story continues below advertisement

The board also officially appointed Victor Mancebo as CEO. Mr. Mancebo had been serving as interim CEO since Feb 12.

**

Mountain Province Diamonds Inc. (MPVD-N; MPVD-T) announced that it has notified Nasdaq Stock Market LLC of its intention to voluntarily delist its common shares from Nasdaq Stock Exchange.

The company noted that it's currently out of compliance with Nasdaq rules, but chose not to apply for an extension to regain compliance. "Given that trading on the Toronto Stock Exchange accounts for a vast majority of the company's current daily trading volume, the costs associated with maintaining this listing are no longer justified," it stated.

The company also said it’s evaluating alternative platforms for future listings in order to increase liquidity.

**

Cott Corp. (COT-N; BCB-T) has signed a deal to sell its S&D Coffee and Tea business to Westrock Coffee Co. LLC for US$405 million.

Story continues below advertisement

The sale is part of Cott’s plan to focus on its water business.

Cott announced an agreement earlier this year to acquire Primo Water Corp.

The company plans to rebrand Cott under the Primo Water name to reflect its new focus.

Westrock Coffee is an integrated coffee company that provides sourcing, financing, supply chain management, roasting, packaging and distribution services.

The deal is expected to close in the first quarter of 2020 and is subject to certain customary closing conditions including regulatory approval.

-The Canadian Press

Story continues below advertisement

**

Calian Group Ltd. (CGY-T) announced the acquisition of two Ottawa-based health companies, Allphase Clinical Research Services Inc. and Alio Health Services Inc. for $14.5-million, including $12-million cash and 62,054 common shares.

The agreement contains two earnout payments on the first- and second-year anniversaries, of $6-million and $6-million respectively, based on the achievement of a certain level of EBITDA in each of those periods, the company stated.

“This strategic acquisition supports all four pillars of our growth framework. It diversifies our customer base into pharmaceuticals, home care and hospitals, and supports Calian’s innovation agenda with services enabled by sophisticated software. We see opportunities to evolve this software within our Health segment and strengthen Calian’s position in technology-enabled health solutions,” stated Kevin Ford, CEO of Calian.

**

MedMen Enterprises Inc. (MMEN-C) announced that co-founder and CEO Adam Bierman has decided to step down as CEO, effective Feb. 1. The board of directors is in the process of forming a committee of directors that will be responsible for identifying and appointing a new CEO, the company said. Meantime, chief operating officer and chief technology officer Ryan Lissack has been named Interim CEO. Mr. Bierman will continue to serve on the company’s board.

Report an error Editorial code of conduct
Tickers mentioned in this story
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies